ViVac Strengthens Leadership and Scientific Advisory Capabilities

ViVac announced the expansion of its leadership and scientific advisory network, adding world-class expertise in synthetic biology, immuno-oncology, and nanomedicine to support its mission of transforming cancer treatment through programmable RNA therapeutics.

The additions build upon the company’s foundation in the Synthetic Biology Lab of Prof. Lior Nissim and the Membrane & Liposome Lab of Prof. Chezy Barenholz, inventor of Doxil® and one of Stanford’s top 2% most-cited scientists. Together, these global experts are shaping ViVac’s technology platform — combining decades of discovery in nanomedicine and RNA engineering to reprogram how tumors are treated.

“Our strength lies in collaboration — bringing together the best minds across science and industry to accelerate innovation,” said Keren Leshem, ViVac’s CEO. “With our expanded leadership team and scientific advisors, we’re building the foundation for a company capable of making a lasting impact in oncology.”

The company continues to engage leading researchers, clinicians, and strategic partners as it prepares for preclinical advancement and future clinical development milestones.